FDA Broadens Pitolisant Label - Summary - MDSpire

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

  • By

  • Kathryn Wighton

  • February 17, 2026

  • 2 min

Share

Objective:

To inform about the expanded approval of pitolisant for treating narcolepsy in pediatric and adult patients.

Approach:
    Key Findings:
    • Pitolisant is the only non-scheduled therapy approved for narcolepsy in both pediatric and adult patients.
    • The drug was initially approved for adults in 2019 and expanded to include pediatric patients in 2024.
    • Common adverse reactions include insomnia, nausea, anxiety in adults, and headache, insomnia in pediatric patients.
    Interpretation:

    The broadened indication for pitolisant enhances treatment options for narcolepsy, addressing both excessive daytime sleepiness and cataplexy in younger patients.

    Limitations:
    • Pitolisant is contraindicated in patients with hypersensitivity or severe hepatic impairment.
    • It may prolong the QT interval, posing risks for patients with cardiac issues.
    Conclusion:

    The FDA's approval of pitolisant for pediatric patients marks a significant advancement in the management of narcolepsy, offering new therapeutic options.

    Sources:

Original Source(s)

FDA Broadens Pitolisant Label

  • by Kathryn Wighton

  • February 17, 2026

Related Content

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.

The Digital Migraine Revolution: How Headache Tracking and Digital Health Are Changing Pediatric Care

Pediatric migraine has historically been managed in fragments – symptoms recalled across months of episodic appointments. At Phoenix Children's, digital tools are reshaping care from episodic to continuous.

  • by

  • June 15, 2026

  • 6 min
Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.